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ABSTRACT 
MICHAEL STELLA: Salivary Inflammatory Biomarkers in a Stent-Induced Biofilm 
Overgrowth Model  
(Under the direction of Dr. Steven Offenbacher) 
 
Introduction: Salivary diagnostics is an emerging field that has promise for improving 
understanding, diagnosis, and treatment of periodontitis. Recent studies showed that 
inflammatory biomarker levels present in saliva have the potential to discriminate between 
disease states and predict disease progression. 
Objective: To determine whether baseline salivary inflammatory biomarkers could 
discriminate between different clinical levels of disease and/or predict clinical progression 
over a 3-week stent-induced biofilm overgrowth (SIBO) period.  
Methods: 165 subjects ranging from healthy to periodontitis were recruited, 33 or 34 subjects 
per group: Healthy (BGI-H), Gingivitis (BGI-G), Mild (BGI-P1), Moderate (BGI-P2), and 
Severe (BGI-P3) Periodontitis. Subjects wore stents to prevent plaque removal during 
brushing over one maxillary and one mandibular posterior dental sextant for 21 days. Clinical 
periodontal parameters and unstimulated saliva samples were collected at screening, baseline, 
and each week during biofilm overgrowth induction. Saliva samples were assessed for levels 
of selected inflammatory biomarkers.  
Results:  Higher salivary levels of IL-1β, MMP-3, MMP-8, MMP-9, and NGAL were found 
in diseased groups compared to healthy at baseline. Higher IL-1ra was found in healthy 
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subjects at baseline. In addition, MMP-1, TIMP-1, TIMP-2, and TIMP-4 levels increased 
during induction across all subject groups.  
Conclusion:  Salivary inflammatory biomarkers differ at baseline by periodontal status and 
show changes in the immunoregulators of host response during an experimental disease 
progression model. 
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CHAPTER 1. INTRODUCTION 
Background 
Periodontal diseases are a heterogeneous group of inflammatory conditions that affect tooth-
supporting tissues
1
. These diseases are broadly grouped into two major categories: gingivitis 
and periodontitis. Gingivitis is reversible and limited to superficial, gingival tissues, whereas 
periodontitis is non-reversible and features tissue destruction extending to deeper tissues such 
as periodontal ligament and alveolar bone. A recent study estimated the prevalence of 
periodontitis in the US greater than 47% for those aged over 30 and 70% for subjects over 65 
years old
2
. Clinical measurements reflect history of disease and have poor reliability for 
predicting disease activity and progression
3
. Furthermore, differentiating periodontitis from 
gingivitis for the purpose of treatment recommendations has proven difficult. Ideally, 
inexpensive, non-invasive tests should allow detection and characterization of disease state, 
aiding in treatment of an under-diagnosed, under-treated disease.  
Periodontitis is known to be a bacterial biofilm and host-response mediated disease. It is 
characterized by periods of activity and remission, which complicates diagnosis and adequate 
prognosis. As dental plaque collects and matures, its initial gram-positive, aerobic coccal 
colonizers become more numerous. After several days, filamentous and rod forms appear 
with a mild leukocytic immune response. At 4-10 days, neutrophils enter the tissues resulting 
in the intensification of gingivitis with edema and spontaneous bleeding, increased probing 
pocket depths, and a switch to a plaque mainly colonized by vibrio and spirochetal species. 
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As the immune response intensifies, macrophages and neutrophils degranulate releasing toxic 
compounds, causing apoptosis and eventually necrosis. The pocket lining ulcerates, and the 
bacteria invade the inner soft tissues, eventually reaching the vascular bed and disseminating 
throughout the body. Monocytes activated by the bacterial lipopolysaccharide (LPS) secrete 
inflammatory mediators such as prostaglandin E2 (PGE2), thromboxane B2, interleukin-1β 
(IL-1β), IL-6, and tumor necrosis factor alpha (TNFα). Macrophages and T-helper cells 
secrete receptor activator of nuclear factor –kappa B ligand (RANKL), leading to an 
increased ratio of RANKL to osteoprotegerin (OPG) and increased binding of RANKL to 
RANK on macrophage precursor cells. This promotes differentiation and activation of the 
precursor cells into osteoclasts, which begin to resorb the adjacent alveolar bone
4
. 
Simultaneously, matrix metalloproteinases (MMPs) are activated and break down proteins in 
the connective tissue surrounding the lesion. In part, the ratio of these MMPs to tissue 
inhibitors of matrix metalloproteinases (TIMPs) determines the relative speed and magnitude 
of tissue destruction
4-6
. The importance of the MMP/TIMP ratio is underscored by studies 
demonstrating tetracycline-like compounds that block MMPs reduce bone and attachment 
loss
7
. 
Data derived from animal models indicate that gingivitis is a precursor to periodontitis
8
. 
However, human population studies clearly demonstrate that not all individuals with 
gingivitis linearly progress to periodontitis 
9, 10
. The host response of an individual is thought 
to be the major determinant of the onset and progression of periodontitis. In a landmark study 
of Sri Lankan tea workers with virtually no oral hygiene, Löe et al. evaluated periodontal 
disease progression and found that 8% of subjects experienced rapid tooth loss, 82% 
moderate loss, and 10% no appreciable periodontitis
9
. Hirschfield and Wasserman 
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categorized their patients by response to therapy, as determined by number of teeth lost over 
more than 15 years of maintenance (average 22, median 20 years), finding that 83% of 
patients were “well-maintained,” losing three or fewer teeth, but that 12% of patients’ status 
trended “downhill,” losing 4-9 teeth, and that 4% were “extreme downhill” cases, losing 10-
23 teeth despite ongoing treatment
11
. Thus, there is a gradient of host response, with some 
individuals exhibiting hyperresponsive, average, or hyporesponsive phenotypes.  
Furthermore, data from cohort studies indicate that a subset of individuals appear to exhibit 
more pronounced local inflammatory changes to the etiologic plaque biofilm as compared to 
others who fail to respond
12-14
. These differences in host susceptibility to periodontal disease 
may be traced to inter-individual differences in environmental exposures or genetic risk 
factors
15
.
 
Accordingly, evidence from studies with human twins indicates that approximately 
50 percent of the inter-individual variability in the expression of periodontal disease may be 
explained by genetic factors
16
. Observational studies suggest that risk for advanced 
periodontitis may be elevated among humans with certain genetic biomarkers or 
polymorphisms (e.g., Interleukin-1B gene)
17, 18
. However, the risk conferred by these 
markers is not consistent among different populations
18
 and may be modified by environment 
and behaviors such as smoking
19
. Genome-wide association studies are identifying new 
candidate loci for investigation and show great promise
20
. 
Papapanou et al. have conducted a pilot study of gene expression signatures in gingival 
tissues obtained from two subsets of periodontitis patients, chronic versus aggressive
21
.
 
The 
results from this study indicate that there is good overall intra-individual agreement in gene 
expression. However, no significant difference in gene expression signatures was noted 
between the two periodontitis cohorts. Nevertheless, the group concluded that gene 
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expression profiling techniques might be useful in the identification of different subclasses of 
periodontal diseases and for distinguishing between health and disease. More recently, the 
same group
22
 characterized differential mRNA expression corresponding to pathogen 
colonization and experimental gingivitis demonstrating upregulation of immune cell response 
pathways. Cumulatively, these studies provide evidence for the potential utility of using 
biochemical mediators for periodontal diagnosis and activity characterization. 
In an in-vitro study, Molvig et al. showed that peripheral monocyte secretion of IL-1, TNFα, 
and PGE2 when stimulated by LPS was variable between subjects but generally stable, and 
that there was an association between low-responder status and human leukocyte antigen 
(HLA) type, establishing a possible genotype/phenotype linkage
23
. In 1992, Pociot et al. 
found a single nucleotide polymorphism (SNP) in the IL-1B gene that led to four-fold greater 
IL-1β production24. When combined with another allelic variant of IL-1A, this SNP 
conferred 18.9-fold greater risk for non-smoking subjects to have severe disease. 
Identification of hyper- and hypo-responsive individuals could allow establishment of 
treatment regimens based on risk profiles and improve patient outcomes. Genotype studies 
are expensive and slow, and are but an indirect predictor of the outcome in question. 
Therefore, measurement of the inflammatory mediators themselves is likely to prove more 
robust for predicting current immediate risk of progression. These mediators, in addition to 
bacteria and bacterial products such as LPS, can be found in gingival crevicular fluid (GCF). 
GCF has been widely analyzed to study disease status and disease progression, since it is 
relatively easy and painless to collect. In addition, GCF is site-specific and requires multiple 
samples for a reliable subject-level analysis. Conversely, saliva provides a combined, whole-
mouth sample for analyses and includes mediators found in the GCF, which pass into the 
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saliva. Recent advances in assay methodologies have overcome the assay problems 
associated with measuring low levels of inflammatory mediators in a complex, viscous 
glycosaminoglycan-rich bodily fluid.  
Salivary diagnostics 
The potential application of new lab-on-chip methods for the saliva-based diagnosis of 
periodontal disease represents an exciting new opportunity that has the potential to move the 
assay from the laboratory to chairside. Combining fast turnaround with non-invasive 
sampling will enable clinicians to stratify patients by risk and allocate treatment accordingly. 
Among potential markers for periodontitis diagnosis and disease progression, interleukins, 
MMPs, and their modifiers have shown promising results.  
IL-1β, a marker of destructive inflammation, is produced by macrophages in response to 
bacterial insult. Along with TNFα, it promotes diapedesis and acute phase response, and acts 
to upregulate inflammatory pathways
25
. Its expression is well known to be upregulated in 
chronic periodontitis, and application of exogenous IL-1β in animal models enhances bone 
loss
26
. Studies have found increased salivary levels of IL-1β and MMP-8 in chronic 
periodontitis patients
27, 28
, and IL-1β increased in aggressive and chronic periodontitis 
compared to healthy patients, and correlated with clinical measures
29
. Recently, Rocha et 
al.
30
 found that in IL-1β levels in dental implant patients differed between patients with 
healthy and inflamed sites, irrespective of whether they were otherwise edentulous. Perhaps 
the most compelling findings for progression come from a five-year longitudinal case-control 
study by Scannapieco et al., who found higher salivary levels of IL-1β in subjects who lost 
alveolar bone
31
. Kaushik found IL-1β elevated in periodontitis patients and decreases after 
initial therapy, though not to the levels of healthy patients 
32
. 
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IL-1 receptor antagonist (IL-1ra) inhibits the destructive action of IL-1β through competitive 
binding to the IL-1 receptor
33
. In an in-vitro study, the monocytes of subjects with chronic 
periodontitis produced significantly less IL-1ra on pathogen stimulation compared to those of 
patients with other types of periodontitis
34
. It can be found in GCF
35
, and Ishihara et al. 
found that the ratio of IL-1 to IL-ra was correlated with alveolar bone loss score in 
periodontitis subjects, though total amount of IL-1ra showed only a non-significant decrease 
in severe bone loss sites.
36
 This ratio has since been confirmed to be correlated with clinical 
signs of disease
37
. Roberts et al. also found increases in both IL-1β and IL-1ra in connective 
tissue biopsies of periodontitis patients
38
, but other studies have found decreased GCF IL-1ra 
levels in diseased sites compared to healthy sites
39, 40
. Holmlund et al. showed significant 
decreases in IL-1β and IL-1ra in GCF following periodontal therapy41. In saliva, Chan et al 
found IL-ra levels to be lower in diabetic periodontitis subjects.
42
 
Interleukin 8 (IL-8) is a cytokine released by monocytes and other cells, including 
fibroblasts
43
 and endothelial cells, upon stimulation by lipopolysaccharide (LPS), IL-1α, IL-
1β, and TNFα. It functions to recruit neutrophils to sites of inflammation and activate them to 
degranulate once there
44
. It is therefore decidedly pro-inflammatory and pro-destructive
45
. It 
has recently been shown to be increased in GCF during experimental gingivitis in smokers
46
 
and in diseased patients.
47, 48
 
Monocyte chemotactic protein-1 (MCP-1, also referred to as chemokine ligand 2 CCL-2) is a 
small chemoattractant cytokine produced by phagocytes and endothelial cells that attracts 
immune cells, chiefly monocytes, to sites of inflammation. Non-inflamed tissues express 
little to no MCP-1, but inflamed tissues show MCP-1-positive cells in numbers that correlate 
to the severity of the inflammation.
26
 MCP-1 has been shown to be increased in GCF in both 
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aggressive periodontitis
49, 50
 and chronic periodontitis
48, 50, 51
. In a mouse model, experimental 
periodontitis was inhibited by blocking the receptor for MCP-1, CCR-2.
52
 It has also been 
shown to decrease to near-healthy levels in the GCF of treated patients.
51, 53
 Recently, MCP 
salivary levels were shown to be higher in disease and to decrease with therapy.
51
 
MMPs are divalent cation-dependent proteases that digest extracellular matrix proteins and 
have been broadly implicated in tissue remodeling in health and disease
54
. Their relative 
abundance compared to their inhibitors (TIMPs) appears to determine the severity and 
progression of tissue destruction.
4
 MMP production by neutrophils, macrophages, epithelial 
cells, and fibroblasts is stimulated by IL-1, IL-8, TNFα, and prostaglandins such as PGE2.
45
 
PCR analysis of gingival biopsies has shown higher MMP levels in periodontitis, with higher 
TIMP levels in subjects exhibiting chronic disease rather than aggressive disease pattern.
6
 
Saliva studies are limited, with two studies showing higher salivary TIMP-1 levels in 
periodontitis subjects.
27, 55
 Other TIMPs do not appear to have been studied in saliva.  
MMP-1 is a collagenase thought to be involved in much general tissue remodeling. MMP-3, 
or stromelysin-1, targets basement membrane components and may also activate other MMPs 
from their inactive proMMP form. Reddy et al. found higher GCF levels of MMP-3 in 
periodontitis patients compared to controls, and SRP reduced those levels significantly.
56
 
MMP-8 is also termed neutrophil collagenase due to its major source. Along with MMP-8, 
MMP-9, or neutrophil gelatinase, is thought to be secreted in a “reactive” rather than 
maintenance pattern, possibly provoked by IL-8.
5
 Yakob et al. recently found the periodontal 
pathogen Treponema denticola to be associated with MMP-8 and -9 in GCF,
57
 and Sorsa et 
al. have proposed MMP-8 as a point-of care marker for periodontitis and cardiovascular 
disease due to its putative predominance as a reactive rather than maintenance MMP
58
. 
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Sexton et al. studied a group of patients assigned to oral hygiene instruction control or 
scaling and root planing (SRP) treatment group. Salivary IL-1β and MMP-8 decreased only 
in SRP patients, and MMP-8 differentially reduced in high responders. Compared to other 
markers, MMP-8 had greatest area under the curve, indicating best predictive value
59
. 
Neutrophil gelatinase-associated lipocalin (NGAL) is an iron-binding glycoprotein that 
functions as part of the innate immune defense to bacterial infection
60
. It is most commonly 
used as a marker of acute kidney injury, but it is elevated (along with MMP-9) in gingival 
tissue in periodontitis, apparently secreted by extravasated neutrophils.
61
 It is thought to 
complex with MMP-9, preventing its degradation and, thereby, prolonging MMP-9’s 
gelatinase activity. The lone reports in the periodontal literature by Sorsa’s group in 199661, 62 
have not since been revisited. 
In a longitudinal study of periodontitis patients, the Giannobile group
63
 investigated 
combining salivary and serum biomarkers with biofilm pathogen levels. In their study, 
subjects who displayed greater than 2mm of attachment loss over a six-month monitoring 
phase clustered into a “progression” group, and models could predict progression or stability 
of clinical signs of disease. They also found that after treatment, salivary levels of MMP-8, 
MMP-9, OPG, and IL-1β were significantly reduced. Those four markers, especially MMP-8, 
were previously described by the same group
64
 as showing high predictability for disease 
severity. 
Experimental gingivitis 
Since the first report in humans in 1965
65
, authors have used a biofilm overgrowth-induced 
experimental gingivitis model to investigate gingival response to undisturbed plaque growth. 
In that study, twelve healthy subjects abstained from oral hygiene measures until overt 
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gingivitis developed due to plaque accumulation, after which time the subjects resumed 
home care, leading to a reversal in clinical and microbiological parameters. In most subjects, 
the induction phase lasted between 15 and 21 days. In one quarter of the subjects, however, 
gingivitis was reached in 10 days or fewer. This provides early evidence for biologic 
phenotypes governing host response to plaque. This phenomenon of “high- and low-
responders” may have some bearing on the transition from gingivitis to periodontitis. 
However, most studies included only patients without periodontitis.  
Recent experimental gingivitis studies
66-68
 have incorporated stents to encourage compliance, 
a method termed stent-induced biofilm overgrowth (SIBO). One such study
66
 analyzed GCF 
samples collected prior to the induction of experimental gingivitis, at the 21-day peak of 
gingival inflammation, and again at resolution of gingivitis and attainment of gingival health 
one week later. The results from this study identified specific inflammatory mediators 
(including MMP-1, IL-1ra and CRP as primary with secondary mediators resistin, IFNγ, 
Complement D, MCP-1, MMP-13, TPO and IL-8) that were predictive of clinical response in 
gingivitis either at baseline or upon initial presentation and illustrated that the dynamics of 
inflammatory mediator change were different among those subjects that were “high 
responders” (i.e. developed more clinical disease) as compared to “low responders” (i.e. 
displayed little change in clinical phenotype, despite plaque overgrowth).  Thus, these 
inflammatory biomarkers were demonstrated to change during the induction and resolution 
of gingival inflammation. Furthermore, the changes in inflammatory biomarkers differed 
with regard to the magnitude of the clinical changes seen in this gingivitis induction model. 
Thus, the goal of this study is to understand whether salivary diagnostics (assaying key 
inflammatory mediators in saliva) can be used to discriminate among health, gingivitis, and 
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three levels of periodontal disease and whether baseline mediator values can predict 
worsening of clinical parameters during SIBO. This study represents the first report of using 
the SIBO model among patients with gingivitis or periodontitis and enables us to explore the 
changes in salivary mediators during disease progression in a short-term, reversible clinical 
model.
  
 
 
 
CHAPTER 2. MATERIALS AND METHODS 
Study design and enrollment 
Five groups of subjects categorized as health, gingivitis, mild, moderate, and severe 
periodontitis were enrolled, stratifying into groups until 33 or 34 subjects were reached per 
group (total subjects, 168), using the biofilm-gingival interface (BGI) criteria previously 
described in 2007 by Offenbacher et al
69
. Subjects with no pockets greater than 3mm were 
classified as healthy (BGI-H) if  bleeding scores were less than 10% or  gingivitis (BGI-G) if 
their bleeding scores were 10% or greater. Subjects with 4mm or greater probing depths (PD) 
were also sorted by based on whether their bleeding scores were less than 10% (BGI-P1), 10-
50% (BGI-P2), or greater than 50% (BGI-P3). Exclusion criteria included gross oral 
pathology, treatment with antibiotics or chronic treatment with medication known to affect 
periodontal status within 1 month prior to enrollment, beginning a new medication for a 
chronic condition less than three months prior to enrollment, clinically significant organ 
disease, severe unrestored caries, or pregnancy or nursing. Full inclusion/exclusion criteria 
and the criteria for subject safety/study exit are listed in appendix C. 
All groups were subjected to a stent-induced biofilm overgrowth model (SIBO) that 
experimentally induced a short-term biofilm overgrowth. In brief, acrylic stents were made 
covering one maxillary and one mandibular posterior sextant of each subject’s dentition. 
Subjects wore the stents while performing oral home care for three weeks to allow biofilm 
accumulation. Subjects were monitored each week for safety to provide escape therapy in the 
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event of more than 2mm PD increase. Subjects exhibiting progression were to be exited from 
the study and given scaling and root planing treatment as a rescue therapy. Subjects were also 
to be exited from the study for changes in medical status or medications, use of mouth rinses, 
or use of non-study dentifrices, toothbrushes, or floss during the induction or resolution 
phases. At the completion of 3 weeks, subjects were instructed to begin brushing again. At 
the end of the study, subjects were given a dental prophylaxis and referred for further care. 
Examiners were masked, and patients were forbidden from using antiseptic rinses. At each 
visit, plaque index
70
, gingival index
71
, probing depths, clinical attachment levels, and 
bleeding on probing were measured, and unstimulated saliva samples were acquired on days 
-14, 0, 7, 14, 21, 35, and 49. At each of these time points, approximately 3 mL of 
unstimulated saliva were collected into a 15 mL plastic conical tube. Participants refrained 
from eating, drinking, chewing gum, breath mints, etc., or performing oral hygiene 
procedures for at least one hour prior to saliva collection. This request was made after 
consenting for the first sample collection. The collection vessel was kept at room 
temperature, centrifuged and aliquoted as three samples of .5 ml in each tube. Remaining 
saliva was aliquoted into a fourth tube. Saliva was stored at -80
0
C. 
These samples were assessed for levels of IL-1β, IL-1ra, IL-8, MCP-1, MMP-1, MMP-3, 
MMP-8, MMP-9, TIMP-1, TIMP-2, TIMP-3, and TIMP-4 using commercially available 
assay kits on the BioPlex 200 by multiplex immunochemistry according to manufacturer’s 
instructions. NGAL levels were measured by enzyme-linked immunosorbent assay (ELISA) 
(R&D Systems, Inc., Minneapolis, MN). Each saliva sample was assayed in duplicate. 
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Statistical analysis 
A pre-study power analysis indicated a minimum sample size of eight test/control pairs to 
yield power of 90% with alpha of 5% for IL-1β changes. Other outcome thresholds were 
unknown, so 33 subjects were enrolled per group with the goal of completing 30, for a total 
of 150 subjects. Clinical and biochemical changes were analyzed across groups using a 
mixed-models analysis. For mediators that showed overall significance between groups, 
generalized linear modeling allowed analysis of each mediator independent of changes of the 
others. 
Changes in clinical signs were used to identify high and low responders dichotomizing on the 
median change in clinical sign at 21 days as compared to baseline. 
  
 
 
 
CHAPTER 3. RESULTS:  
Demographics and safety 
Subjects did not differ significantly between groups for most variables, but there were some 
differences. Healthy and gingivitis groups had more African Americans, were younger, and 
had lower BMI than the periodontitis groups. No subjects were exited due to increasing of 
PD>2mm. Subjects with increasing PD during the SIBO were found to respond to therapy at 
exit with PD returning to baseline or improving from baseline. No subjects experienced 
irreversible loss of attachment.  
Salivary mediators at baseline and during SIBO 
Significant differences (p < 0.05) were found at baseline between groups for IL-1β, MMP-3, 
MMP-8, MMP-9, TIMP-3, IL-1ra, and NGAL (table 4). P3 subjects had significantly higher 
log mean values (see figures 2-5, 8) than other groups for IL-1β, MMP-3, MMP-8, MMP-9, 
and NGAL. Compared to healthy subjects, P3 subject levels were more than two-fold 
elevated for IL-1β, MMP-3, MMP-9, and TIMP-3, and more than five-fold elevated for 
MMP-8.  
Mean TIMP-3 was significantly lower for P2 than for other groups (fig 6). Mean IL-1ra was 
higher in H than for G or P1 and higher in P2 than in G or P1 (fig 7).  
Significant increases in saliva values from baseline to peak induction were found for MMP-1, 
TIMP-1, TIMP-2, and TIMP-4 (table 5) pooling all subjects. When subdivided by disease 
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category there were no significant changes in salivary biomarker level during SIBO 
induction. No mediator showed a significant decrease during the induction phase. 
Clinical changes 
Subjects showed significant increases in plaque, gingival index, and bleeding on probing 
across all groups (table 4). The gingivitis subjects also showed slight but significant increase 
in attachment loss (0.11 ± 0.05mm, p=0.03) during SIBO. P1 subjects showed small but 
significant increase in pocket depth (0.11 ± 0.05mm, p=0.047).  
Grouped together, Health + Gingivitis subjects showed increases in pocket depth (0.11 ± 
0.05mm, p=.04) and attachment loss (0.09 ± 0.03mm, p=.008).  
Baseline predictors of clinical changes 
A stepwise linear regression model using all salivary biomarkers demonstrated that IL-1ra 
(p=0.0044) and IL-6 (p=0.0093) were the two best predictors of change in probing depths 
during the induction phase, with an overall r
2
 value of 0.37. The effect slope for IL-1ra was 
positive (0.675) and negative for IL-6 (-0.246). There were no significant salivary predictors 
of change in bleeding or change in gingival index. 
  
 
 
 
CHAPTER 4. DISCUSSION: 
This study has shown significant baseline differences between subject groups, but no 
differences in response to SIBO. There is some controversy over saliva should be stimulated 
prior to collection, as studies have demonstrated
72
 differences in lactoferrin and other anti-
bacterial compounds by collection strategy. In this study, since the goal was to study local 
accumulation of cytokines from GCF washout into saliva, a stimulated collection strategy 
would unnecessarily dilute samples, potentially increasing error. Therefore, unstimulated 
saliva was collected for analysis.  
Differences between groups may have influenced the results obtained. The severe 
periodontitis group (P3) had fewer African Americans. The periodontitis subjects were older, 
as a group, than the healthy/gingivitis subjects were. Prevalence of periodontitis increases 
with age, so this is not surprising. They also had a higher mean BMI. Saito et al.
73
 first 
described a Japanese population in which periodontitis was associated with obesity (BMI > 
30), with an odds ratio of OR = 8.6. Obesity is a source of oxidative stress and leads to 
increased serum levels of IL-6 and CRP, as does periodontitis.
74
 
The BGI case definitions, designed to differentiate between subject phenotypes, segregate 
subjects into disease categories by bleeding levels rather than by the more traditionally used 
percentage of deep pockets and attachment levels or bone loss. For this reason, some subjects 
categorized P1 would fit under the American Academy of Periodontology definition of 
 17 
 
gingivitis rather than periodontitis.
1
 The BGI groups purposefully ignore attachment loss to 
allow investigators to concentrate on inflammatory burden and host response to present 
disease rather than its history.  
The most obvious differences at baseline were between the P3 group and all other subjects. 
The finding of significant differences in IL-1β, MMP-3, MMP-8, MMP-9, TIMP-3, IL-1ra, 
and NGAL between groups is in contrast to that of Teles et al, who found no significant 
differences in salivary granulocyte-macrophage colony-stimulating factor, IL-1β, IL-2 IL-4, 
IL-5, IL-6, IL-8, IL-10, IFNγ, or TNFα between healthy and periodontitis subjects, though 
there were some differences when analyzed based on pocket depths, bleeding, and 
attachment levels.
75
 Their study might have shown differences between groups had they 
grouped by BGI classification rather than traditional definition. However, our results confirm 
those of several other studies showing higher levels of IL-1β27-29, 31, 32, 59, 76-78, MMP-827, 28, 55, 
59, 64, 78
, and MMP-9
64, 79
 in the saliva of periodontitis subjects. Westerlund et al. also found 
NGAL in periodontitis subject saliva, but no statistical analysis was presented.
61
 
Increases in plaque, gingival index, and bleeding on probing across all groups are to be 
expected in an experimental gingivitis study. Several mediators, including MMP-1, TIMP-1, 
TIMP-2, and TIMP-4 increased significantly from baseline to peak of induction (table 5). To 
our knowledge, this is the first human study demonstrating changes in TIMPs during 
experimental gingivitis. These increases ranged from 1.12-1.48 –fold changes, smaller than 
the baseline differences for the mediators that were significantly different between groups. 
The increased levels of TIMPs may be due to a local response to dampen inflammation and 
prevent protein degradation. MMPs are generally produced in an inactive (proMMP) form 
and must be cleaved to become functional. It is possible an assay of the collagenolytic 
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activity of saliva would be more useful than one of collagenase concentration alone in 
showing tissue response to bacterial stimulation. One study found significant differences in 
GCF MMP-8 activity by diagnosis and by time point during treatment.
80
 The same group
81
 
showed the activity levels did not correlate significantly with Western blot analysis of 
zymogen vs. active form. MMP-3, MMP-8, and MMP-9 did not significantly increase during 
induced gingivitis in this study. Possible explanations include the possibility that initial 
changes are mostly expressed by enzymes being cleaved into their active forms, a three-week 
study may be too short to induce measurable changes in the amounts of these enzymes, or the 
effect size may be too small when covering only two sextants and diluting in saliva.  
Baseline IL-1ra and IL-6 levels were found to be significant predictors of change in probing 
depths. The r
2 
value of 0.37 is rather low, implying that they do not alone predict the bulk of 
changes, as might be expected in a chronic, complex disease system. IL-1ra is the antagonist 
for IL-1β receptor, blocking its action. As IL-1β is a pro-inflammatory molecule, high levels 
of its receptor antagonist could indicate a compensatory mechanism of negative feedback or 
the release of molecules that are normally tissue-bound. IL-6 was not significant between 
groups at baseline. However, high levels at baseline predicted an increase in PD. IL-6 is 
known to be a pro-inflammatory molecule that shift the immune response from toward a cell-
mediated reaction, is elevated in chronic periodontitis and decreases with periodontal 
therapy.
74
  
Future directions: 
The markers chosen for this study have good evidence for showing baseline differences and 
changes during induction. However, some other cytokines could have been used as well. 
TNFα is a macrophage-produced pyrogen that stimulates acute inflammation, apoptosis, 
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neutrophil chemotaxis, and bone resorption. It has been shown experimentally to accelerate 
bone loss in mice, and knockout mice have much lower levels of other inflammatory 
cytokines and less bone loss
26
. In addition, TNFα antagonists have been shown to reduce 
bone loss in experimental periodontitis
4
. Frodge et al. 
82
 found increased salivary TNFα 
levels in periodontitis patients compared to healthy controls. In their study, TNFα levels 2 
standard deviations above median were predictive for increased probing depth, bleeding on 
probing, and attachment loss. Fine et al. found A.a. –positive subjects who developed 
aggressive periodontitis to have had 50-fold elevated macrophage inflammatory protein 
(MIP-1α) six to nine months prior to radiographic evidence of bone loss.83 Analysis of these 
salivary samples for TNFα and MIP-1α levels might yield data helpful for diagnosis and 
gauging risk of progression. 
Several studies
36, 37
 have found the ratio of IL-1β to IL-1ra to be more meaningful in 
periodontitis than absolute values of either mediator, and efforts to change that ratio through 
supplying exogenous IL-1ra have promise, as shown by the use of human recombinant forms 
of  IL-1ra (anakinra) to limit host response in other chronic inflammatory diseases such as 
rheumatoid arthritis,
84
 gout,
85
 osteoarthritis,
86
 and cardiovascular disease.
87
 Perhaps analysis 
of this ratio in our cohort would yield informative data.  
Recent studies have begun to profile the salivary metabolome. In a longitudinal study, 
Nomura et al. 
88
 found aspartate aminotransferase, alanine aminotransferase, and lactate 
dehydrogenase to be increased at baseline in patients who later experienced progression. 
Parwani et al. showed higher salivary levels of nitric oxide in gingivitis and periodontitis 
patients versus healthy controls. After treatment, these numbers were reduced as compared to 
pre-treatment levels
89
. Combining cytokines like those assayed in this study with salivary 
 20 
 
compounds, such as enzymes and bacterial breakdown products, may increase the predictive 
power of salivary analysis. Elsewhere, our group will investigate the metabolomes of these 
samples.  
Salivary diagnostics is emerging as a valuable possible method of determining disease 
presence, severity, and activity. In this study, there were significant differences at baseline 
between the severe periodontitis group and all other groups. There were also limited 
increases in markers during gingivitis induction, notably MMP-1 and TIMPs. More study is 
needed to determine whether techniques and markers can be combined to improve the 
diagnostic and prognostic abilities of salivary testing.  
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Table 1: Study Design 
PHASES 
LEAD-IN ORAL 
HYGIENE PHASE 
NO ORAL HYGIENE IN STENT AREA 
PHASE 
Procedure Screen  Day-14 Baseline (Day 0) Day 7 Day 14 Day 21 
Visit 1 2 3 4 5 6 
Informed Consent X      
Medical History/Updates  X X X X X X 
Vital Signs X X X X X X 
Height and weight / Demographics X      
Inclusion/Exclusion Criteria - 
pregnancy test if applicable 
X      
Stent Impressions X      
Deliver Stent   X    
Discontinue Stent      X 
Continuance Criteria  X X X X X 
Oral Cancer Screening, Plaque and 
Gingival Indices, PD, CAL & BOP  
X X X X X X 
Adverse Events  X X X X X 
Unstimulated Saliva Collection  X X X X X 
GCF collection  X X X X X 
Subgingival Plaque Collection  X X   X 
 
 22 
 
Table 2: Demographics by BGI Category 
 H G P1 P2 P3 p-value 
Female 23 (20.5%) 23 (20.5%) 23 (20.5%) 23 (20.5%) 20 (17.9%)  
Male 10 (17.9%) 11 (19.6%) 10 (17.9%) 11 (19.6%) 14 (25.0%) 0.87 
African American 21 (20.8%) 26 (25.7%) 23 (22.8%) 16 (15.8%) 15 (14.9%)  
  Caucasian 7 (13.7%) 6 (11.8%) 7 (13.7%) 17 (33.3%) 14 (27.5%)  
  Other 5 (33.3%) 2 (13.3%) 3 (20.0%) 1 (6.7%) 4 (26.7%) 0.03 
Diabetic 3 (42.9%) 0 (0.0%) 1 (14.3%) 1 (14.3%) 2 (28.6%)  
  No 30 (18.6%) 34 (21.1%) 32 (19.9%) 33 (20.5%) 32 (19.9%) 0.41 
Current Smoker 3 (14.3%) 5 (23.8%) 7 (33.3%) 3 (14.3%) 3 (14.3%)  
  No 30 (20.6%) 29 (19.9%) 26 (17.8%) 31 (21.2%) 30 (20.6%) 0.47 
Mean (StdErr) Age 30.3 (1.9) 29.6 (1.9) 36.5 (1.9) 37.0 (1.9) 34.4 (1.9) 0.01 
Mean (StdErr) BMI 28.1 (1.3) 24.5 (1.2) 27.4 (1.3) 30.7 (1.2) 29.6 (1.2) 0.008 
Table 2: Significant differences were found between groups for ethnic background (p=0.03), 
age (0.01), and BMI (0.008).  
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Table 3:   Baseline log10 Mean (StdErr) Saliva Mediator by BGI Category.  
 
 Health G1 P1 P2 P3 Overall 
 p-value 
IL-1β 2.43 (0.07) 2.46 (0.07) 2.45 (0.07) 2.47 (0.07) 2.76 (0.07) 0.004 
IL-8 2.75 (0.06) 2.80 (0.06) 2.77 (0.06) 2.78 (0.06) 2.98 (0.06) 0.07 
MCP-1 2.28 (0.06) 2.44 (0.06) 2.45 (0.06) 2.49 (0.06) 2.48 (0.06) 0.07 
MMP-1 1.50 (0.17) 1.35 (0.17) 1.59 (0.18) 1.18 (0.15) 1.13 (0.17) 0.24 
MMP-3 1.94 (0.11) 1.94 (0.11) 1.88 (0.11) 1.94 (0.10) 2.34 (0.11) 0.02 
MMP-8 4.70 (0.10) 4.85 (0.10) 4.76 (0.10) 4.94 (0.09) 5.42 (0.10) <0.0001 
MMP-9 4.92 (0.07) 4.98 (0.07) 4.93 (0.08) 5.05 (0.08) 5.39 (0.08) <0.0001 
TIMP-1 5.26 (0.05) 5.24 (0.05) 5.18 (0.05) 5.08 (0.05) 5.21 (0.05) 0.15 
TIMP-2 4.53 (0.04) 4.78 (0.04) 4.50 (0.04) 4.45 (0.04) 4.62 (0.04) 0.06 
TIMP-3 1.49 (0.24) 1.93 (0.24) 1.56 (0.24) 0.67 (0.24) 1.81 (0.24) 0.003 
TIMP-4 1.11 (0.04) 1.11 (0.04) 1.08 (0.04) 1.05 (0.04) 1.14 (0.04) 0.67 
IL-1ra 5.79 (0.07) 5.58 (0.07) 5.57 (0.07) 5.83 (0.07) 5.72 (0.07) 0.03 
NGAL 2.51 (0.05) 2.48 (0.05) 2.60 (0.05) 2.54 (0.05) 2.75 (0.05) 0.005 
Table 3: Significant differences were found between groups for IL-1β (p=.004), MMP-3 
(p=.02), MMP-8 (p<.0001), MMP-9 (p<.0001), TIMP-3 (p=.003), IL-1ra (p=.03), and NGAL 
(p=.005). 
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Table 4:  Mean (StdErr) Delta Clinical Sign (Day 21-Day 0) During Induction by BGI 
Group 
BGI (Health)   p value 
  Plaque 0.85 (0.11) <0.0001 
  Gingival Index 0.44 (0.06) <0.0001 
  Bleeding On Probing 19.4 (4.03) <0.0001 
  Probing Depth 0.05 (0.06) 0.46 
  Attachment Level -0.08 (0.05) 0.12 
BGI (Gingivitis)   
  Plaque 0.79 (0.09) <0.0001 
  Gingival Index 0.29 (0.05) <0.0001 
  Bleeding On Probing 20.5 (3.49) <0.0001 
  Probing Depth 0.18 (0.09) 0.052 
  Attachment Level -0.11 (0.05) 0.03 
BGI (P1)   
  Plaque 0.70 (0.10) <0.0001 
  Gingival Index 0.21 (0.05) 0.0001 
  Bleeding On Probing 21.0 (4.47) <0.0001 
  Probing Depth 0.11 (0.05) 0.047 
  Attachment Level 0.01 (0.05) 0.91 
BGI (P2)   
  Plaque 0.82 (0.10) <0.0001 
  Gingival Index 0.28 (0.06) 0.0001 
  Bleeding On Probing 15.7 (4.05) 0.0005 
  Probing Depth 0.03 (0.06) 0.67 
  Attachment Level 0.03 (0.06) 0.63 
BGI (P3)   
  Plaque 0.65 (0.08) <0.0001 
  Gingival Index 0.15 (0.04) 0.002 
  Bleeding On Probing 8.30 (4.47) 0.07 
  Probing Depth -0.06 (0.06) 0.30 
  Attachment Level 0.02 (0.08) 0.79 
BGI (Health + Gingivitis)   
  Plaque 0.82 (0.07) <0.0001 
  Gingival Index 0.37 (0.04) <0.0001 
  Bleeding On Probing 19.9 (2.67) <0.0001 
  Probing Depth 0.11 (0.05) 0.04 
  Attachment Level -0.09 (0.03) 0.008 
BGI (P1-P3)   
  Plaque 0.73 (0.05) <0.0001 
  Gingival Index 0.22 (0.03) <0.0001 
  Bleeding On Probing 15.8 (2.51) <0.0001 
  Probing Depth 0.02 (0.03) 0.48 
  Attachment Level 0.02 (0.04) 0.66 
Table 4: Clinical parameters for teeth in SIBO sextants, stratified by BGI group.  
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Table 5:  Mixed Models:  Log10 Mean (StdErr) Saliva Mediator by time point.   
    p-value 
 Baseline Peak -fold change B/L-Peak 
IL-1b 2.51 (0.03) 2.50 (0.03) 0.98 0.60 
IL-8 2.81 (0.03) 2.82 (0.03) 1.02 0.73 
MCP-1 2.43 (0.03) 2.44 (0.03) 1.02 0.39 
MMP-1 1.34 (0.08) 1.51 (0.08) 1.48 0.002 
MMP-3 2.01 (0.05) 1.97 (0.04) 0.91 0.39 
MMP-8 4.94 (0.05) 4.89 (0.05) 0.89 0.20 
MMP-9 5.05 (0.04) 5.07 (0.04) 1.05 0.55 
TIMP-1 5.20 (0.02) 5.28 (0.02) 1.20 0.0002 
TIMP-2 4.52 (0.02) 4.60 (0.02) 1.20 <0.0001 
TIMP-3 1.50 (0.11) 1.56 (0.11) 1.15 0.12 
TIMP-4 1.10 (0.02) 1.15 (0.02) 1.12 0.03 
IL-1ra 5.70 (0.03) 5.72 (0.02) 1.05 0.42 
NGAL 2.58 (0.02) 2.57 (0.02) 0.98 0.76 
 
Table 5: Clinical parameters for teeth in SIBO sextants, stratified by BGI group.  
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Figure 1: Study Design 
 
Figure 1. Study design. At screening visit, inclusion/exclusion/continuance criteria were 
reviewed and subjects were enrolled. At each visit, saliva was collected and examinations 
were conducted, with measurements of probing depths, clinical attachment loss, plaque 
index, and gingival index. At day 21, subjects resumed brushing.   
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Figure 2: IL-1β Baseline Values Box Plot
 
Figure 2. IL-1β baseline differences were significant overall between groups and 
individually for P3 vs. H (P=0.0008), G (P = 0.0024), P1 (P = 0.0021), and P2 (P = 0.0035). 
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Figure 3: MMP-3 Baseline Values Box Plot 
 
Figure 3. MMP-3 baseline differences were significant overall between groups and 
individually for P3 vs. H (P = 0.0093), G (P = 0.0096), P1 (P = 0.0039), and P2 (P = 0.0061). 
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Figure 4: MMP-8 Baseline Values Box Plot 
 
Figure 4. MMP-8 baseline differences were significant overall between groups and 
individually for P3 vs. H (P < 0.0001), G (P < 0.0001), P1 (P = < 0.0001), and P2 (P = 
0.0004). 
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Figure 5: MMP-9 Baseline Values Box Plot 
 
Figure 5. MMP-9 baseline differences were significant overall between groups and 
individually for P3 vs. H (P < 0.0001), G (P = 0.0002), P1 (P < 0.0001), and P2 (P = 0.0019). 
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Figure 6: TIMP-3 Baseline Values Box Plot 
 
Figure 6. TIMP-3 baseline differences were significant overall between groups and 
individually for P2 vs. H (P = 0.0154), G (P = 0.0003), P1 (P = 0.0097), and P3 (P = 0.0011). 
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Figure 7: IL-1ra Baseline Values Box Plot 
 
Figure 7. IL-1ra baseline differences were significant overall between groups and 
individually for H vs. G (P = 0.0418), H vs. P1 (P = 0.0303), G vs. P2 (P = 0.0141), and P1 
vs. P2 (P = 0.0099). 
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Figure 8: NGAL Baseline Values Box Plot 
 
Figure 8. NGAL baseline differences were significant overall between groups and 
individually for P3 vs. H (P = 0.0017), G (P = 0.0005), P1 (P = 0.0475), and P2 (P = 0.0076). 
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Inclusion criteria: 
 
 Participants must be adult males or females aged 18-75. 
 Participants must be willing and able to follow study procedures and instructions. 
 Participants must have read, understood, and signed informed consent. 
 Participants must present with at least eight teeth in the functional dentition with a 
minimum of three adjacent teeth with interproximal papilla in each posterior sextant that 
will have the stent. 
 Participants must be in good general health.  
 Participants must present with one of the following five categories to be considered for 
enrollment  
o BGI-Health  (all PD<3mm, BOP<10%) 
o BGI-Gingivitis  (all PD≤3mm, BOP≥10%) 
o BGI-P1   (1+ site with PD>3mm, BOP≤10%) 
o BGI-P2   (1+ site with PD>3mm, BOP>10% but BOP≤50%)  
o BGI-P3   (1+ site with PD>3mm, BOP>50%)  
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Exclusion criteria 
 
 Individuals who have a chronic disease with oral manifestations or active infectious 
diseases such as hepatitis, HIV, or tuberculosis. 
 Individuals who exhibit gross oral pathology. 
 Treatment with antibiotics for any medical or dental condition within 1 month prior to the 
screening examination. 
 Chronic treatment (i.e., two weeks or more) with any medication known to affect 
periodontal status (e.g., phenytoin, calcium antagonists, cyclosporine, anticoagulants, 
non-steroidal anti-inflammatory drugs, high dose aspirin such as >100mg per day) within 
one month of the screening examination.  
 Ongoing medications initiated less than three months prior to enrollment (i.e., 
medications for chronic medical conditions must be initiated at least three months prior to 
enrollment). 
 Participants with clinically significant organ disease including impaired renal function, 
and/or any bleeding disorder. 
 Severe unrestored caries or any condition that is likely to require antibiotic treatment 
during the study, including the need for prophylactic antibiotic. 
 Individuals who are pregnant, or expect to become pregnant within the next three months 
and individuals nursing. 
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Exit Criteria 
 
 Changes in participant’s medical status or medications 
 Use of mouth rinses (e.g. chlorhexidine, Listerine®, or hydrogen peroxide products) 
 Use of non-study dentifrices, toothbrush, dental floss (e.g. triclosan or stannous fluoride 
products) during the study 
 Use of irrigating devices or other interdental aids 
 Inability or noncompliance to wear stents over the selected no-hygiene sextants during 
daily brushing procedures 
 Use of oral antibiotics or non-steroidal anti-inflammatory drugs  
 Progression of periodontitis, defined as PD or CAL change >2mm or suppuration at any 
site 
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